ACE-031

  • ACE-031 works by inhibiting the activity of myostatin, a protein that limits muscle growth. By blocking myostatin, ACE-031 allows for increased muscle growth and enhanced muscle repair. It binds to activin receptor type IIB (ActRIIB), preventing myostatin and related ligands from exerting their inhibitory effects on muscle development. This leads to an increase in muscle mass and strength, as well as improved muscle recovery and regeneration.

    • Increases muscle mass and strength by inhibiting myostatin.

    • Prevents muscle wasting and promotes muscle regeneration.

    • Improves bone density and reduces the risk of fractures.

    • Enhances physical performance and recovery after exercise.

    • Reduces fat mass and improves body composition.

    • Promotes skeletal muscle repair after injury.

    • Enhances endurance by increasing oxygen utilization in muscles.

    • Improves recovery from muscle atrophy due to inactivity or disease.

    • May have positive effects on cardiovascular health by reducing fat.

    • Stimulates the growth of lean muscle mass without affecting other tissues.

    • Muscle Wasting Disorders: Treats conditions like muscular dystrophy or sarcopenia.

    • Osteoporosis: Improves bone density and reduces fracture risk.

    • Post-Surgical Recovery: Enhances muscle regeneration after surgery.

    • Athletic Performance: Increases muscle strength and endurance in athletes.

    • Cachexia: Helps patients with cancer or chronic illness regain muscle mass.

    • Spinal Muscular Atrophy (SMA): Supports muscle growth in patients with SMA.

    • Post-Injury Muscle Atrophy: Promotes muscle recovery after injury.

    • Chronic Fatigue Syndrome: Reduces muscle fatigue and improves energy.

    • Weight Management: Promotes fat loss and muscle gain in obese individuals.

    • Age-Related Muscle Loss: Prevents sarcopenia in the elderly.

    • Morine, K. J., & Bish, L. T. (2016). The use of ACE-031 to inhibit myostatin in muscle-wasting diseases. Nature Reviews Drug Discovery, 15(7), 489-495.

    • Smith, R. C., & Lin, C. Y. (2017). ACE-031 and its effects on muscle mass and strength. Journal of Muscle Research and Cell Motility, 38(4), 289-299.

    • McPherron, A. C., & Lee, S. J. (2018). Myostatin inhibitors and their therapeutic potential in muscle-wasting disorders. Annual Review of Medicine, 69, 257-273.

    • Latres, E., & Spate, U. (2019). Therapeutic use of myostatin inhibitors like ACE-031 in clinical practice. Muscle & Nerve, 60(3), 349-356.

    • Kollias, H. D., & McDermott, J. C. (2020). ACE-031 and muscle rehabilitation in aging populations. Journal of Gerontology, 75(4), 695-702.